

Program	Tumor Type	Phase 1	Phase 2	Phase 3
ADCETRIS®	Diffuse large B-cell lymphoma			*
	Hodgkin lymphoma (HL)			
	HL or PTCL (unfit for combination chemotherapy)		*	
	HL and PTCL		*	
	HL (pediatrics)			
	PTCL (<10% CD30 expression)			
	Metastatic solid tumors			
PADCEV®	Locally advanced or metastatic urothelial cancer			*
	Muscle invasive bladder cancer			*
	Locally advanced or metastatic solid tumors			
	Non-muscle invasive bladder cancer			
TUKYSA®	HER2+ metastatic breast cancer			*
	High risk HER2+ breast cancer			*
	HER2+ metastatic breast cancer			
	HER2+ metastatic colorectal cancer		*	
	HER2+ gastroesophageal cancer		*	
	Metastatic solid tumors HER2 alterations			
	HER2+ gastric cancer			
TIVDAK™	Locally advanced solid tumors			
	Metastatic solid tumors			
	Platinum-resistant ovarian cancer			
Disitamab vedotin	HER2+ urothelial cancer			
Ladiratumumab vedotin	Metastatic triple-negative breast cancer			
	Metastatic solid tumors			
	Metastatic breast cancer			
SEA-CD40	Solid tumors			
SEA-TGT	Solid tumors			
SEA-BCMA	Multiple myeloma			
SEA-CD70	MDS / AML			
SGN-CD228A	Solid tumors			
SGN-B6A	Solid tumors			
SGN-STNV	Solid tumors			

The safety and efficacy of the above investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.

\* Registrational intent